Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections
Phase 4
Terminated
- Conditions
- Neovascular Age-related Macular DegenerationRetinal Vein OcclusionDiabetic Macular Edema
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Retina Vitreous Associates of Florida
- Target Recruit Count
- 10
- Registration Number
- NCT04563299
- Locations
- 🇺🇸
Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States
Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
Not Applicable
Completed
- Conditions
- Age-related Macular DegenerationCentral Retinal Vein OcclusionDiabetic Macular Edema
- Interventions
- Procedure: Xylocaine 2% Injectable AnestheticDrug: Proparacaine Hydrochloride 0.5% DropDrug: Tetravisc 0.5% GelDrug: AcuvailDrug: Intra-vitreal Anti-VEGF Drug
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Retina Vitreous Associates of Florida
- Target Recruit Count
- 57
- Registration Number
- NCT01640171
- Locations
- 🇺🇸
Retina Vitreous Associates of Florida, Clearwater, Florida, United States
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Retina Vitreous Associates of Florida
- Target Recruit Count
- 20
- Registration Number
- NCT01476449
- Locations
- 🇺🇸
Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath